{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:31:49Z","timestamp":1780083109546,"version":"3.54.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,3]]},"DOI":"10.7759\/cureus.89296","type":"journal-article","created":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T20:17:32Z","timestamp":1754252252000},"source":"Crossref","is-referenced-by-count":1,"title":["Hearing Loss in Leucine-Rich Glioma-Inactivated 1 Encephalitis: Cochlear Implantation Considerations"],"prefix":"10.7759","author":[{"given":"Nawfal","family":"Saleem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbae155","article-title":"Anti-LGI1 antibody-associated encephalitis misdiagnosed as schizophrenia: A case report","volume":"50","author":"Zhang JH","year":"2024","unstructured":"Zhang JH, Fu BB, Wang W, Sun CC, Xu JJ. Anti-LGI1 antibody-associated encephalitis misdiagnosed as schizophrenia: A case report. Schizophr Bull. 2024, 50:1273-6. 10.1093\/schbul\/sbae155","journal-title":"Schizophr Bull"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2015.10.010","article-title":"Jerking & confused: Leucine-rich glioma inactivated 1 receptor encephalitis","volume":"289","author":"Casault C","year":"2015","unstructured":"Casault C, Alikhani K, Pillay N, Koch M. Jerking & confused: Leucine-rich glioma inactivated 1 receptor encephalitis. J Neuroimmunol. 2015, 289:84-6. 10.1016\/j.jneuroim.2015.10.010","journal-title":"J Neuroimmunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003173","article-title":"Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up","volume":"87","author":"van Sonderen A","year":"2016","unstructured":"van Sonderen A, Thijs RD, Coenders EC, et al.. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology. 2016, 87:1449-56. 10.1212\/WNL.0000000000003173","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-315720","article-title":"LGI1, CASPR2 and related antibodies: A molecular evolution of the phenotypes","volume":"89","author":"Binks SN","year":"2018","unstructured":"Binks SN, Klein CJ, Waters P, Pittock SJ, Irani SR. LGI1, CASPR2 and related antibodies: A molecular evolution of the phenotypes. J Neurol Neurosurg Psychiatry. 2018, 89:526-34. 10.1136\/jnnp-2017-315720","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.43","article-title":"The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis","volume":"13","author":"van Sonderen A","year":"2017","unstructured":"van Sonderen A, Petit-Pedrol M, Dalmau J, Titulaer MJ. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. Nat Rev Neurol. 2017, 13:290-301. 10.1038\/nrneurol.2017.43","journal-title":"Nat Rev Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.813487","article-title":"Case report: Anti-LGI1 encephalitis following COVID-19 vaccination","volume":"12","author":"Zlotnik Y","year":"2021","unstructured":"Zlotnik Y, Gadoth A, Abu-Salameh I, Horev A, Novoa R, Ifergane G. Case report: Anti-LGI1 encephalitis following COVID-19 vaccination. Front Immunol. 2021, 12:813487. 10.3389\/fimmu.2021.813487","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.014","article-title":"Hearing loss in autoimmune disorders: Prevalence and therapeutic options","volume":"17","author":"Mancini P","year":"2018","unstructured":"Mancini P, Atturo F, Di Mario A, et al.. Hearing loss in autoimmune disorders: Prevalence and therapeutic options. Autoimmun Rev. 2018, 17:644-52. 10.1016\/j.autrev.2018.01.014","journal-title":"Autoimmun Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/392820-hearing-loss-in-leucine-rich-glioma-inactivated-1-encephalitis-cochlear-implantation-considerations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T20:17:32Z","timestamp":1754252252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/392820-hearing-loss-in-leucine-rich-glioma-inactivated-1-encephalitis-cochlear-implantation-considerations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,3]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.89296","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,3]]}}}